Exhibit 99.1

        MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES COMPLETION OF DEVELOPMENT
      OF ITS OPTICAL BIOPSY CANER DIAGNOSTIC RATIOMETER(TM) AND SUBMISSION
                  TO THE FDA OF THE PRE-IDE BRIEFING MATERIALS

CHERRY HILL, NEW JERSEY (Dec 8, 2004) - Mediscience  Technology Corp. (otc-MDSC)
announced  today  that its  wholly  owned  New York  subsidiary,  Medi-Photonics
Development  LLC,  has  completed  development  of  its  Optical  Biopsy  Cancer
Diagnostic   Ratiometer(TM)   for  the   molecular   detection   of  cancer  and
physiological  change.  The Company also  announced  that it had  submitted  its
Pre--IDE  briefing  materials to the United States Food and Drug  Administration
(FDA).

President  and Chief  Operating  Officer  Michael  Engelhart  stated "The timely
completion of our Optical Biopsy Cancer Diagnostic  Ratiometer should provide us
with a clear path for our applications  platform  commercialization in the early
detection and  diagnosing of cancers of the cervix,  mouth  esophagus and gastro
intestinal  tract."  Engelhart  added "We have  submitted  our  initial  Pre-IDE
briefing materials for detecting cancer of the cervix with the FDA for marketing
in the U.S."

                                      # # #

Safe  Harbor  Statement:  To the extent that any  statements  made in this press
release  contain  information  that  is not  historical,  these  statements  are
essentially forward-looking. Forward-looking statements can be identified by the
use  of  words  such  as  "expects,"  "plans,"  "will,"  "may,"   "anticipates,"
"believes,"  "should,"  "intends,"  "estimates,"  and  other  words  of  similar
meaning.  These statements are subject to risks and uncertainties that cannot be
predicted or quantified and, consequently,  actual results may differ materially
from those expressed or implied by such forward-looking  statements.  Such risks
and  uncertainties  include,  among others,  the ability of the Company to raise
capital  to  finance  the  development  of its  Internet  services  and  related
software,  the  effectiveness,  profitability  and the  marketability  of  those
services, the ability of the Company to protect its proprietary  information and
to retain and expand its user base, the establishment of an efficient  corporate
operating  structure  as the  Company  grows  and,  other  risks  detailed  from
time-to-time  in our filings with the  Securities and Exchange  Commission.  The
Company  undertakes  no  obligation  to  publicly  update  any   forward-looking
statements.